Showing 1 - 6 results of 6 for search 'Harry P Erba', query time: 0.03s
Refine Results
-
1
Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. by Kentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, Larisa Pereboeva, Donna Salzman, Harry P Erba, Lawrence S Lamb, Ravi Bhatia, Shin Mineishi, Antonio Di Stasi
Published 2017-01-01
Article -
2
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients by Era L. Pogosova-Agadjanyan, Xing Hua, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, Harry P. Erba, Matthew P. Fitzgibbon, Isaac C. Jenkins, Min Fang, Stanley C. Lee, Anna Moseley, Jasmine Naru, Jerald P. Radich, Jenny L. Smith, Brooke E. Willborg, Cheryl L. Willman, Feinan Wu, Soheil Meshinchi, Derek L. Stirewalt
Published 2023-03-01
Article -
3
S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FRO... by Richard Schlenk, Pau Montesinos, Antonio Romero-Aguilar, Radovan Vrhovac, Elżbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, James Hanyok, LI Liu, Yasser Mostafa Kamel, Aziz Benzohra, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Alexander E. Perl, Mark J. Levis, Harry P. Erba
Published 2023-08-01
Article -
4
P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL by Mark J Levis, Harry P. Erba, Pau Montesinos, Radovan Vrhovac, Elżbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, Jaime E. Connolly Rohrbach, Ken C.N. Chang, James Hanyok, LI Liu, Yasser Mostafa Kamel, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, Alexander E. Perl
Published 2023-08-01
Article -
5
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report by Era L. Pogosova-Agadjanyan, Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, I-Ming L. Chen, Harry P. Erba, John E. Godwin, Isaac C. Jenkins, Min Fang, Mike Huynh, Kenneth J. Kopecky, Alan F. List, Jasmine Naru, Jerald P. Radich, Emily Stevens, Brooke E. Willborg, Cheryl L. Willman, Brent L. Wood, Qing Zhang, Soheil Meshinchi, Derek L. Stirewalt
Published 2020-08-01
Article -
6
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry by Daniel A. Pollyea, Tracy I. George, Mehrdad Abedi, Rafael Bejar, Christopher R. Cogle, Kathryn Foucar, Guillermo Garcia‐Manero, David L. Grinblatt, Rami S. Komrokji, Jaroslaw P. Maciejewski, Dennis A. Revicki, Gail J. Roboz, Michael R. Savona, Bart L. Scott, Mikkael A. Sekeres, Michael A. Thompson, Sandra E. Kurtin, Chrystal U. Louis, Melissa Nifenecker, E. Dawn Flick, Arlene S. Swern, Pavel Kiselev, David P. Steensma, Harry P. Erba
Published 2020-07-01
Article